Sterne Agee Sees 16% Upside for Actavis, Initiates Coverage With Buy Rating

Loading...
Loading...
Shares of Actavis
ACT
are up 2.3 percent to $198.42 in Wednesday's trading after Sterne Agee initiated coverage on the stock with a Buy rating and $230 price target. Analyst Shibani Malhotra sees upside “to the company's pro-revenue and synergy targets, and expects management to continue to implement on its disciplined inorganic growth strategy.” The analyst is also bullish on the company's growth profile “post its recent merger with Forest Laboratories
FRX
.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsMoversShibani MalhotraSterne Agee
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...